1-[4,4'-difluorodiphenylmethoxy]-3-chloropropane | 120737-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[4,4'-difluorodiphenylmethoxy]-3-chloropropane
• 英文别名: Benzene, 1,1'-[(3-chloropropoxy)methylene]bis[4-fluoro-；1-[3-chloropropoxy-(4-fluorophenyl)methyl]-4-fluorobenzene
• CAS: 120737-98-6
• 化学式: C₁₆H₁₅ClF₂O
• 分子量: 296.744
• InChiKey: HUTPJDNRDUHAQE-UHFFFAOYSA-N

物化性质

• 沸点：
  354.4±37.0 °C(Predicted)
• 密度：
  1.209±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲基哌啶-4-酮盐酸盐 、 1-[4,4'-difluorodiphenylmethoxy]-3-chloropropane 在 sodium iodide 、 potassium carbonate 作用下， 以 水 、 乙腈 为溶剂， 生成 1-[1-(4,4'-difluorodiphenylmethoxy)-propyl]-3-methylpiperidine-4-one
  参考文献：
  名称：

  N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine

  摘要：

  本发明涉及通式（I）的取代氮杂环衍生物，其为外消旋或光学纯形式和/或顺反异构体形式，其药学上可接受的盐，并用于制备具有心理活性，特别是抗抑郁活性的药物。

  公开号：

  US05846980A1
• 作为产物：
  描述：

  4,4'-二氟二苯甲醇 、 3-氯-1-丙醇 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 生成 1-[4,4'-difluorodiphenylmethoxy]-3-chloropropane
  参考文献：
  名称：

  New N-(benzhydryloxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity

  摘要：

  Several benzhydryloxylalkylpiperidine derivatives were prepared with the aim of obtaining new antidepressant compounds. The influence of the length of the aliphatic chain and of aromatic and piperidine ring substitutions was studied. The pharmacological activity of compounds was investigated in vivo by means of a screening comprising four pharmacological tests: antagonism of reserpine and apomorphine hypothermia; increase of yohimbine induced mortality; and antagonism of immobility in tail suspension test. An in-depth pharmacological study was performed with the more active compounds and a binding study to serotonin (5-HT), norepinephrine (NE) and dopamine (DA) reuptake sites was performed for the preferred compounds. The most active compounds [+], [-]-cis-31, 32 and 46 exhibited an interesting psychopharmacological profile after intraperitoneal administration. This profile was confirmed by the oral route for 31 and 46. In vitro, these compounds showed a non-selective inhibition of DA, NE and 5-HT uptake.

  DOI：

  10.1016/s0223-5234(97)83972-4

文献信息

• Method of improving sleep
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0285219A2

  公开（公告）日：1988-10-05

  The use for the manufacture of a medicament for improving sleep and treating sleep disorders of a piperazine derivative of formula wherein R1 is hydrogen or C, alkyl; X is C16 alkyl, hydroxyC, 6 alkyl, C, alkyloxyC16 alkyl, aminocarbonyl, mono-and di(C16 alkyl)-aminocarbonyl, carboxyl, C, alkyloxycarbonyl, (aminocarbonyl)C16 alkyl, [mono-and di(C, alkyl)-aminocarbonyl]C16 alkyl, carboxylC, 6 alkyl, (C, 6 alkyloxycarbonyl)C, alkyl or (hydroxyC16alkyl)-aminocarbonyl; R2 is hydrogen or C, 6 alkyl; Ar is phenyl, pyridinyl, pyrazolyl, all three being optionally substituted, or a radical of formula Q is aryl, aryloxy, diarylmethoxy, 2,2-diarylethenyl, diarylmethylcarbonyl, arylcarbonyl, mono-and diarylaminocarbonyl, diarylmethyl or arylamino, the amino moiety in said arylamino being optionally substituted, the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof; novel compounds of formula (I); pharmaceutical compositions containing the latter compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  式中的哌嗪衍生物用于制造改善睡眠和治疗睡眠障碍的药物 其中R1为氢或C, 烷基； X是C16烷基、羟基C，6烷基、C，6烷氧基C16烷基、氨基羰基、单和二(C16烷基)-氨基羰基、羧基、C，6烷氧基羰基、(氨基羰基)C16烷基、[单和二(C，烷基)-氨基羰基]C16烷基、羧基C，6烷基、(C，6烷氧基羰基)C，烷基或(羟基C16烷基)-氨基羰基； R2 是氢或 C, 6 烷基； Ar 是苯基、吡啶基、吡唑基（三者均可选择被取代）或式中的一个基团 Q 是芳基、芳氧基、二芳甲氧基、2,2-二芳基乙烯基、二芳甲基羰基、芳基羰基、单芳基和二芳基氨基羰基、二芳甲基或芳基氨基，所述芳基氨基中的氨基被任选取代；药学上可接受的酸加成盐及其可能的立体化学异构形式；式 (I) 的新型化合物；含有后一种化合物作为活性成分的药物组合物以及制备所述化合物和药物组合物的方法。
• Agents for improving sleep
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0727421A1

  公开（公告）日：1996-08-21

  A chemical compound having the formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, R1 and R2each independently are hydrogen or C1-6alkyl; Xis C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonyl, mono- and di(C1-6alkyl)aminocarbonyl, carboxyl, C1-6alkyloxycarbonyl, (aminocarbonyl)C1-6alkyl, [mono- and di(C1-6alkyl)aminocarbonyl]C1-6alkyl, carboxylC1-6alkyl, (C1-6alkyloxycarbonyl)C1-6alkyl or (hydroxyC1-6alkyl)aminocarboxyl; mis 1 or 2; n is 1 to 4; Aris optionally substituted phenyl; optionally substituted pyridinyl; optionally substituted pyrazolyl; or a radical of formula Q' is arylethyl, arylethenyl, aryloxymethyl, diarylmethoxy, 2,2-diarylethenyl, diarylmethylcarbonyl, arylcarbonylmethyl, mono- and diarylaminocarbonyl, diarylethyl or arylaminomethyl. Process for preparing said compounds and pharmaceutical compositions comprising them are also disclosed.

  一种化合物，其化学式为 药学上可接受的酸加成盐及其立体异构体、 R1和R2各自独立地为氢或C1-6烷基； X是C1-6烷基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、氨基羰基、单-和二(C1-6烷基)氨基羰基、羧基、C1-6烷氧基羰基、(氨基羰基)C1-6烷基、[单-和二(C1-6烷基)氨基羰基]C1-6烷基、羧基C1-6烷基、(C1-6烷氧基羰基)C1-6烷基或(羟基C1-6烷基)氨基羰基； mis为1或2；n为1至4； Aris 任选取代的苯基；任选取代的吡啶基；任选取代的吡唑基；或式中的一个基团 Q'是芳基乙烷基、芳基乙烯基、芳基氧甲基、二芳基甲氧基、2,2-二芳基乙烯基、二芳基甲基羰基、芳基羰基甲基、单芳基和二芳基氨基羰基、二芳基乙烷基或芳基氨基甲基。 此外，还公开了制备上述化合物的工艺和包含这些化合物的药物组合物。
• DERIVES DE N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE COMME AGENTS ANTIDEPRESSIFS
  申请人：COOPERATION PHARMACEUTIQUE FRANCAISE

  公开号：EP0751937A1

  公开（公告）日：1997-01-08
• US4880808A
  申请人：——

  公开号：US4880808A

  公开（公告）日：1989-11-14
• US4968684A
  申请人：——

  公开号：US4968684A

  公开（公告）日：1990-11-06